SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 228 filers reported holding SAGE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21 | -55.3% | 1 | 0.0% | 0.00% | – |
| Q2 2023 | $47 | +11.9% | 1 | 0.0% | 0.00% | – |
| Q1 2023 | $42 | +10.5% | 1 | 0.0% | 0.00% | – |
| Q4 2022 | $38 | – | 1 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 1 | -93.3% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 15 | -71.2% | 0.00% | – |
| Q4 2021 | $2,000 | 0.0% | 52 | 0.0% | 0.00% | – |
| Q3 2021 | $2,000 | +100.0% | 52 | +173.7% | 0.00% | – |
| Q2 2021 | $1,000 | – | 19 | +90.0% | 0.00% | – |
| Q1 2021 | $0 | -100.0% | 10 | -95.6% | 0.00% | -100.0% |
| Q4 2019 | $16,000 | -48.4% | 226 | 0.0% | 0.00% | -50.0% |
| Q3 2019 | $31,000 | -22.5% | 226 | 0.0% | 0.00% | -33.3% |
| Q2 2019 | $40,000 | +14.3% | 226 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $35,000 | +105.9% | 226 | +25.6% | 0.00% | +50.0% |
| Q4 2018 | $17,000 | -29.2% | 180 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $24,000 | -11.1% | 180 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $27,000 | +237.5% | 180 | +221.4% | 0.00% | +100.0% |
| Q1 2018 | $8,000 | – | 56 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |